Compare MFC & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFC | ZTS |
|---|---|---|
| Founded | 1887 | 1952 |
| Country | Canada | United States |
| Employees | 37000 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6B | 49.7B |
| IPO Year | N/A | 2012 |
| Metric | MFC | ZTS |
|---|---|---|
| Price | $39.26 | $114.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $52.00 | ★ $154.18 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.40% | 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $40.66 | $5.63 |
| Revenue Next Year | $6.23 | $4.77 |
| P/E Ratio | ★ $16.52 | $19.11 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $29.70 | $112.97 |
| 52 Week High | $39.33 | $172.23 |
| Indicator | MFC | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 68.22 | 40.01 |
| Support Level | $35.99 | N/A |
| Resistance Level | N/A | $129.28 |
| Average True Range (ATR) | 0.61 | 2.85 |
| MACD | 0.02 | -0.49 |
| Stochastic Oscillator | 77.50 | 7.92 |
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 21% of 2025 adjusted earnings. The Asia segment operates across 12 countries and contributes around 38% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 16% of earnings. Manulife's global asset and wealth management business contributes approximately 25% of its earnings and had around CAD 1.1 trillion in assets under management and administration as of the end of 2025.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.